Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV
1/2상
완료
NCT03141060
| 대상 질환 | Tuberculosis, HIV Infections |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 37 명 |
|---|
| 중재(약물) | Delamanid, Optimized multidrug background regimen (OBR) for children with MDR-TB |
|---|
| 시작일 | 2019년 2월 18일 |
|---|
| 완료일 | 2025년 4월 22일 |
|---|
| 결과 공개일 | 2026년 6월 25일 |
|---|
요약
This Phase I/II study evaluated the pharmacokinetics, safety, and tolerability of the anti-tuberculosis (TB) drug delamanid (DLM) in combination with an optimized multidrug background regimen (OBR) for multidrug-resistant tuberculosis (MDR-TB) in children with MDR-TB with and without HIV.
Percentage of Participants With Adverse Events of ≥ Grade 3 Severity
Measured from entry through Week 24 · percentage of participants
| Cohort 1 (>=12 to < 18 Years) | 18.2 percentage of participants |
|---|
| Cohort 2 (>=6 to < 12 Years) | 25.0 percentage of participants |
|---|
| Cohort 3 (>=3 to < 6 Years) | 33.3 percentage of participants |
|---|
| Cohort 4 (>=0 to < 3 Years) | 25.0 percentage of participants |
|---|
Percentage of Participants With Adverse Events of ≥ Grade 3 Assessed by the Core Team to be at Least Possibly Related to the Study Drug
Measured from entry through Week 24 · percentage of participants
| Cohort 1 (>=12 to < 18 Years) | 9.1 percentage of participants |
|---|
| Cohort 2 (>=6 to < 12 Years) | 25.0 percentage of participants |
|---|
| Cohort 3 (>=3 to < 6 Years) | 0.0 percentage of participants |
|---|
| Cohort 4 (>=0 to < 3 Years) | 0.0 percentage of participants |
|---|
Percentage of Participants Who Were Terminated From Study Treatment Due to a Drug-related Adverse Event
Measured from entry through Week 24 · percentage of participants
| Cohort 1 (>=12 to < 18 Years) | 9.1 percentage of participants |
|---|
| Cohort 2 (>=6 to < 12 Years) | 12.5 percentage of participants |
|---|
| Cohort 3 (>=3 to < 6 Years) | 0.0 percentage of participants |
|---|
| Cohort 4 (>=0 to < 3 Years) | 0.0 percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.